Abstract:ID 92941 Poster Board 546 Ebola virus (EBOV), a negative-sense RNA virus, is zoonotic pathogen that causes severe hemorrhagic fever with high case fatality rates in humans. EBOV disease outbreaks have been occurring since 1976. The largest outbreaks took place in West African in 2014 and resulted in over 28,000 cases and 11,000 deaths. There have been advances in the development of EBOV vaccines and monoclonal antibodies. However, no antiviral drugs are yet approved, especially for the treatment of pan-filovirus infections. EBOV transcription requires viral VP30 and VP35 proteins, which, according to our recently conducted global proteomic study (1), are phosphorylated in the EBOV virions. Phosphorylation of VP35 on Thr-210 regulated EBOV transcriptional activity and VP35 interaction with EBOV-NP (1). Host protein phosphatases, PP1 and PP2A were shown to facilitate EBOV transcription and replication (2,3). Our unpublished observations indicate that NP E619K mutant binds stronger to PP1 and that binding compromises formation of EBOV capsid. Thus, targeting PP1 might be a valuable approach for EBOV inhibition. Recent high throughout screen conducted in Mathieu Bollen's laboratory at KULeuven identified several gold-containing compounds including FDA approved Auranofin among 400,000 compounds that were screened for PP1 as target. Here we tested the effect of Auranofin and chloro-gold compounds on EBOV transcription and replication and NP interaction with VP35. Auranofin inhibited EBOV minigenome (IC 50 = 0.5 μM) and also potently inhibited EBOV and MARV replication in Vero E6 cells at submicromolar concentrations. Compared to chloro-gold compound, Auranofin showed at least 10-times better efficacy and also less toxicity. To determine the mechanism of Auranofin action, we investigated its effect on the NP-VP35 and NP-NP interactions using split NanoBiT assay. Auranofin potently inhibited NP binding to VP35 in split NanoBiT (IC 50 = 3 μM) comparing to chloro-gold (IC 50 = 12 μM). Auranofin demonstrated low cytotoxicity (IC 50 >300 μM) in 293T cells that were used for the split NanoBiT. Auranofin also showed potent inhibition of NP-NP interaction in split NanoBiT (IC 50 = 1 μM) comparing to chloro-gold (IC 50 = 3 μM). Taken together, our study suggests that Auranofin may serve as EBOV inhibitor by targeting EBOV NP-VP35 and NP-NP interactions. As Auranofin is approved for human use for rheumatoid arthritis, it is feasibly can be further tested as an inhibitor for EBOV and MARV infections References Ivanov A, ... Bukreyev A, Nekhai S. 2020. Global phosphoproteomic analysis of Ebola virions reveals a novel role for VP35 phosphorylation-dependent regulation of genome transcription. Cell Mol Life Sci 77:2579–2603. Ilinykh PA, ... Nekhai S, Bukreyev A. 2014. Role of protein phosphatase 1 in dephosphorylation of Ebola virus VP30 protein and its targeting for the inhibition of viral transcription. J Biol Chem 289:22723–38. Kruse T, ... Nilsson J, Becker S. 2018. The Ebola Virus Nucleoprotein Recruits the Host PP2A-B56 Phosphatase to Activate Transcriptional Support Activity of VP30. Mol Cell 69:136–145 e6 Acknowledgements: We thank Dr. Mathieu Bollen for sharing screening data, Dr. Elke Mühlberger for providing the EBOV minigenome, and Dr. Yoshihiro Kawaoka for providing the plasmids expressing EBOV NP, VP35, L, VP30, and the T7 polymerase. This project was supported by the NIH Research Grants U19AI109664, 5U54MD007597, 2R01HL125005 and P30AI117970

A pan-orthoebolavirus neutralizing antibody encoded by mRNA effectively prevents virus infection

Potent Neutralizing Monoclonal Antibodies Against Ebola Virus Infection

Structural and Molecular Basis for Ebola Virus Neutralization by Protective Human Antibodies

Development and Characterization of Neutralizing Antibodies Against Zaire Ebolavirus Glycoprotein and Protein 40

Discovery of an antibody for pan-ebolavirus therapy

Fully human monoclonal antibodies against Ebola virus possess complete protection in a hamster model

A broadly-neutralizing antibody against Ebolavirus glycoprotein that potentiates the breadth and neutralization potency of other antibodies

Novel Cross-Reactive Monoclonal Antibodies against Ebolavirus Glycoproteins Show Protection in a Murine Challenge Model

Identification and Characterization of a Novel Single Domain Antibody Against Ebola Virus

A novel MARV glycoprotein-specific antibody with potentials of broad-spectrum neutralization to filovirus

Structural basis of broad ebolavirus neutralization by a human survivor antibody

Identification of mpox M1R and B6R monoclonal and bispecific antibodies that efficiently neutralize authentic mpox virus

Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge

RBD-mRNA Vaccine Induces Broadly Neutralizing Antibodies Against Omicron and Multiple Other Variants and Protects Mice from SARS-CoV-2 Challenge.

Chemically Modified Human Serum Albumin Potently Blocks Entry of Ebola Pseudoviruses and Viruslike Particles

Therapeutic Monoclonal Antibodies for Ebola Virus Infection Derived from Vaccinated Humans

Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma

Antibody-dependent-cellular-cytotoxicity-inducing antibodies significantly affect the post-exposure treatment of Ebola virus infection

Auranofin Inhibits Ebola Virus Replication by Targeting NP-VP35 and NP-NP Interactions

Novel neutralization mechanism of a human antibody with pan-coronavirus reactivity

Potent and broadly neutralizing antibodies against sarbecoviruses elicited by single ancestral SARS-CoV-2 infection